ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Pfizer, Eli Lilly and Novo Nordisk side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Pfizer×Eli Lilly×Novo Nordisk×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PfizerEli LillyNovo Nordisk
studies on the registry4,0732,2621,454
open to participants now147173114
phase 3 studies under way9910455
reach primary completion within a year9310463
programswith a study of their own in two years91+9 named only93+3 named only43+14 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePfizerEli LillyNovo Nordisk
Phase 1

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%

Novo Nordisk: 26 of its 43 programs at phase 1

  1. NNC0537-1482phase 1
  2. NNC0442-0344phase 1
  3. NNC0581-0001phase 1
  4. coramitugphase 1
  5. Gastric Inhibitory Polypeptidephase 1

and 21 more — sign in to see them all

60%
Phase 2

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%

Novo Nordisk: 6 of its 43 programs at phase 2

  1. NNC0662-0419phase 2
  2. UBT251phase 2
  3. CDR132Lphase 2
  4. NNC0519-0130phase 2
  5. zalferminphase 2

and 1 more — sign in to see them all

14%
Phase 3

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%

Novo Nordisk: 7 of its 43 programs at phase 3

  1. zenagamtidephase 3
  2. cagrilintidephase 3
  3. etavopivatphase 3
  4. ziltivekimabphase 3
  5. efruxiferminphase 3

and 2 more — sign in to see them all

16%
Approved, new studies

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%

Novo Nordisk: 4 of its 43 programs at approved, new studies

  1. Semaglutideapproved, new study
  2. Liraglutideapproved, new study
  3. insulin icodecapproved, new study
  4. recombinant FVIIaapproved, new study
9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
Novo Nordisk24 readouts · 4 phase 3·

Novo Nordisk, Dec ’26: 4 programs whose next study reaches primary completion

  1. Liraglutideapproved, new study · Dec 13 · NCT07225816
  2. Semaglutideapproved, new study · Dec 13 · NCT07225816
  3. NNC0662-0419phase 2 · Dec 14 · NCT07184632
  4. CDR132Lphase 2 · Dec 31 · NCT07656454

Novo Nordisk, Jan ’27: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. UBT251phase 2 · Jan 14 · NCT07395687
  2. NNC0537-1482phase 1 · Jan 15 · NCT07218627
  3. NNC4004-0002phase 1 · Jan 19 · NCT06859073
  4. NNC6989-0001phase 1 · Jan 21 · NCT07437079
  5. insulin icodecapproved, new study · Jan 25 · NCT07076199

and 3 more — sign in to see them all

Novo Nordisk, Feb ’27: 1 program whose next study reaches primary completion

  1. NNC0442-0344phase 1 · Feb 5 · NCT07220564

Novo Nordisk, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cagrilintidephase 3 · Mar 1 · NCT07011667
·

Novo Nordisk, May ’27: 2 programs whose next study reaches primary completion

  1. NNC4005-001phase 1 · May 14 · NCT07214870
  2. coramitugphase 1 · May 30 · NCT07448623
··

Novo Nordisk, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. NNC0705-0002phase 1 · Aug 1 · NCT07797855
  2. NNC6022-0004phase 1 · Aug 3 · NCT07693868
  3. etavopivatphase 3 · Aug 20 · NCT05953584
  4. recombinant FVIIaapproved, new study · Aug 26 · NCT07157423

Novo Nordisk, Sep ’27: 3 programs whose next study reaches primary completion

  1. NNC0642-1895phase 1 · Sep 12 · NCT07829406
  2. INV-347phase 1 · Sep 15 · NCT07153172
  3. NNC0721-8060phase 1 · Sep 23 · NCT07767175

Novo Nordisk, Oct ’27: 1 program whose next study reaches primary completion

  1. NNC0581-0001phase 1 · Oct 11 · NCT06891365
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 7

Eli Lilly

New programs 8

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Novo Nordisk

New programs 5

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 41 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionPfizerEli LillyNovo Nordisk
Obesityall three · compare here

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Eli Lilly in Obesity: 18 programs

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. macupatidephase 2

and 13 more — sign in to see them all

Their studies: Eli Lilly’s studies of Obesity in search

Novo Nordisk in Obesity: 19 programs

  1. zenagamtidephase 3
  2. cagrilintidephase 3
  3. NNC0662-0419phase 2
  4. UBT251phase 2
  5. NNC0519-0130phase 2

and 14 more — sign in to see them all

Their studies: Novo Nordisk’s studies of Obesity in search

Diabetes Mellitus, Type 2all three · compare here

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Eli Lilly in Diabetes Mellitus, Type 2: 10 programs

  1. orforglipronphase 3
  2. retatrutidephase 3
  3. macupatidephase 2
  4. naperiglipronphase 2
  5. mazdutidephase 2

and 5 more — sign in to see them all

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 2 in search

Novo Nordisk in Diabetes Mellitus, Type 2: 13 programs

  1. zenagamtidephase 3
  2. cagrilintidephase 3
  3. efruxiferminphase 3
  4. NNC0662-0419phase 2
  5. UBT251phase 2

and 8 more — sign in to see them all

Their studies: Novo Nordisk’s studies of Diabetes Mellitus, Type 2 in search

Carcinoma, Non-Small-Cell Lungall three · compare here

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Eli Lilly in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. olomorasibphase 3
  2. Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408phase 1
  3. abemaciclibapproved, new study
  4. selpercatinibapproved, new study

Their studies: Eli Lilly’s studies of Carcinoma, Non-Small-Cell Lung in search

Novo Nordisk in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Digoxinphase 1

Their studies: Novo Nordisk’s studies of Carcinoma, Non-Small-Cell Lung in search

Alzheimer Diseaseall three · compare here

Pfizer in Alzheimer Disease: 1 program

  1. PF-08161842phase 1

Their studies: Pfizer’s studies of Alzheimer Disease in search

Eli Lilly in Alzheimer Disease: 5 programs

  1. remternetugphase 3
  2. LY4405094phase 1
  3. LY3439539phase 1
  4. LY4560736phase 1
  5. donanemabapproved, new study

Their studies: Eli Lilly’s studies of Alzheimer Disease in search

Novo Nordisk in Alzheimer Disease: 1 program

  1. Semaglutideapproved, new study

Their studies: Novo Nordisk’s studies of Alzheimer Disease in search

Diabetes Mellitusall three · compare here

Pfizer in Diabetes Mellitus: 1 program

  1. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus in search

Eli Lilly in Diabetes Mellitus: 1 program

  1. retatrutidephase 3

Their studies: Eli Lilly’s studies of Diabetes Mellitus in search

Novo Nordisk in Diabetes Mellitus: 4 programs

  1. zenagamtidephase 3
  2. NNC0519-0130phase 2
  3. Semaglutideapproved, new study
  4. Liraglutideapproved, new study

Their studies: Novo Nordisk’s studies of Diabetes Mellitus in search

Neoplasmsall three · compare here

Pfizer in Neoplasms: 2 programs

  1. polfurmetinibphase 1
  2. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Eli Lilly in Neoplasms: 3 programs

  1. LY4066708phase 1
  2. LY4214835phase 1
  3. LY4336619phase 1

Their studies: Eli Lilly’s studies of Neoplasms in search

Novo Nordisk in Neoplasms: 1 program

  1. Digoxinphase 1

Their studies: Novo Nordisk’s studies of Neoplasms in search

Heart Failureall three · compare here

Pfizer in Heart Failure: 1 program

  1. PF-07328948phase 2

Their studies: Pfizer’s studies of Heart Failure in search

Eli Lilly in Heart Failure: 1 program

  1. LY3971297phase 1

Their studies: Eli Lilly’s studies of Heart Failure in search

Novo Nordisk in Heart Failure: 3 programs

  1. ziltivekimabphase 3
  2. CDR132Lphase 2
  3. NNC0537-1482phase 1

Their studies: Novo Nordisk’s studies of Heart Failure in search

Hypertensionall three · compare here

Pfizer in Hypertension: 1 program

  1. Prazosinphase 1

Their studies: Pfizer’s studies of Hypertension in search

Eli Lilly in Hypertension: 1 program

  1. orforglipronphase 3

Their studies: Eli Lilly’s studies of Hypertension in search

Novo Nordisk in Hypertension: 1 program

  1. cagrilintidephase 3

Their studies: Novo Nordisk’s studies of Hypertension in search

Liver Diseasesall three · compare here

Pfizer in Liver Diseases: 1 program

  1. osivelotorphase 3

Their studies: Pfizer’s studies of Liver Diseases in search

Eli Lilly in Liver Diseases: 1 program

  1. lepodisiranphase 3

Their studies: Eli Lilly’s studies of Liver Diseases in search

Novo Nordisk in Liver Diseases: 1 program

  1. etavopivatphase 3

Their studies: Novo Nordisk’s studies of Liver Diseases in search

Sleep Apnea, Obstructiveall three · compare here

Pfizer in Sleep Apnea, Obstructive: 1 program

  1. berobenatidephase 3

Their studies: Pfizer’s studies of Sleep Apnea, Obstructive in search

Eli Lilly in Sleep Apnea, Obstructive: 1 program

  1. eloralintidephase 3

Their studies: Eli Lilly’s studies of Sleep Apnea, Obstructive in search

Novo Nordisk in Sleep Apnea, Obstructive: 1 program

  1. UBT251phase 2

Their studies: Novo Nordisk’s studies of Sleep Apnea, Obstructive in search

Breast Neoplasms2 of 3 · compare here

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Eli Lilly in Breast Neoplasms: 4 programs

  1. Imlunestrantphase 3
  2. tersolisibphase 3
  3. GRPR-targeting Radioconjugate LY4257496phase 1
  4. abemaciclibapproved, new study

Their studies: Eli Lilly’s studies of Breast Neoplasms in search

–
Diabetes Mellitus, Type 12 of 3 · compare here–

Eli Lilly in Diabetes Mellitus, Type 1: 4 programs

  1. macupatidephase 2
  2. LY3938577phase 2
  3. LY4057996phase 1
  4. Tirzepatideapproved, new study

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 1 in search

Novo Nordisk in Diabetes Mellitus, Type 1: 6 programs

  1. zalferminphase 2
  2. NNC0497-0040phase 1
  3. NNC0471-0119phase 1
  4. NNC0363-1063phase 1
  5. Liraglutideapproved, new study

and 1 more — sign in to see them all

Their studies: Novo Nordisk’s studies of Diabetes Mellitus, Type 1 in search

Show all 41

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Pfizer 67 of 91 · Eli Lilly 50 of 93 · Novo Nordisk 17 of 43 programs (45 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9, Eli Lilly: 3, Novo Nordisk: 14).